Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 997 drug-target rows in SSL view, for TSG = SMARCA4.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib SMARCA4 KIT 7
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab SMARCA4 RET 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab SMARCA4 KIT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab SMARCA4 VEGFA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) SMARCA4 RET 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) SMARCA4 KIT 4
crizotinib SMARCA4 ALK 7
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine SMARCA4 VEGFA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCA4 RET 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCA4 KIT 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCA4 ALK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCA4 MST1R 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCA4 SMO 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCA4 CDK6 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCA4 FGFR3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMARCA4 BTK 3
bevacizumab SMARCA4 VEGFA 3
crizotinib SMARCA4 MST1R 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan SMARCA4 TOP1MT 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan SMARCA4 TOP1 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan SMARCA4 FGFR3 3
lurbinectedin, irinotecan SMARCA4 TOP1MT 3
lurbinectedin, irinotecan SMARCA4 TOP1 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone SMARCA4 RXRB 3
pembrolizumab, belzutifan, lenvatinib SMARCA4 RET 3
pembrolizumab, belzutifan, lenvatinib SMARCA4 KIT 3
pembrolizumab, belzutifan, lenvatinib SMARCA4 FGFR3 3
abemaciclib SMARCA4 CDK6 7
avapritinib SMARCA4 KIT 7
ibrutinib SMARCA4 BTK 7
nintedanib SMARCA4 FGFR3 7
palbociclib SMARCA4 CDK6 7
pazopanib SMARCA4 KIT 7
pazopanib SMARCA4 FGFR3 7
regorafenib SMARCA4 RET 7
regorafenib SMARCA4 KIT 7
sacituzumab govitecan SMARCA4 TOP1 7
topotecan SMARCA4 TOP1 7
trastuzumab deruxtecan SMARCA4 TOP1 5
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin SMARCA4 VEGFA 2
5fu, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin SMARCA4 VEGFA 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMARCA4 RET 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMARCA4 ALK 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMARCA4 FGFR3 2
alectinib, stereotactic radiosurgery SMARCA4 ALK 2
alvocidib, paclitaxel SMARCA4 CDK9 2
alvocidib, paclitaxel SMARCA4 CDK6 2
apatinib, irinotecan SMARCA4 TOP1MT 2
apatinib, irinotecan SMARCA4 TOP1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan SMARCA4 TOP1MT 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan SMARCA4 TOP1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine SMARCA4 TOP1MT 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine SMARCA4 TOP1 2
bbi-355, erlotinib, futibatinib SMARCA4 FGFR3 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SMARCA4 KIT 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SMARCA4 VEGFA 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SMARCA4 BTK 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis SMARCA4 VEGFA 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib SMARCA4 CDK6 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging SMARCA4 TLR9 2
bortezomib SMARCA4 PSMB5 2
bryostatin 1, paclitaxel SMARCA4 PRKCE 2
cabozantinib SMARCA4 RET 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib SMARCA4 RET 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy SMARCA4 CA3 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery SMARCA4 TOP1MT 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery SMARCA4 TOP1 2
cpt- 11, cisplatin, celecoxib, radiation, surgery SMARCA4 CA3 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab SMARCA4 CDK6 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib SMARCA4 RET 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib SMARCA4 ALK 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study SMARCA4 HDAC3 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study SMARCA4 HDAC2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a SMARCA4 RET 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a SMARCA4 KIT 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a SMARCA4 FGFR3 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide SMARCA4 TOP1MT 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide SMARCA4 TOP1 2
irinotecan, capecitabine SMARCA4 TOP1MT 2
irinotecan, capecitabine SMARCA4 TOP1 2
irinotecan, docetaxel SMARCA4 TOP1MT 2
irinotecan, docetaxel SMARCA4 TOP1 2
lenvatinib, pembrolizumab SMARCA4 RET 2
lenvatinib, pembrolizumab SMARCA4 KIT 2
lenvatinib, pembrolizumab SMARCA4 FGFR3 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate SMARCA4 RET 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate SMARCA4 KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate SMARCA4 FGFR3 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab SMARCA4 TOP1MT 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab SMARCA4 TOP1 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells SMARCA4 CHRNB4 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SMARCA4 RET 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SMARCA4 KIT 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SMARCA4 FGFR3 2
motexafin gadolinium, radiation therapy SMARCA4 RRM2 2
nintedanib, pembrolizumab SMARCA4 FGFR3 2
osimertinib, bevacizumab, osimertinib SMARCA4 VEGFA 2
pd-1 inhibitor, bevacizumab, carboplatin, cisplatin, pemtrexed SMARCA4 VEGFA 2
pembrolizumab, guadecitabine, mocetinostat SMARCA4 HDAC3 2
pembrolizumab, guadecitabine, mocetinostat SMARCA4 HDAC2 2
pembrolizumab, lenvatinib SMARCA4 RET 2
pembrolizumab, lenvatinib SMARCA4 KIT 2
pembrolizumab, lenvatinib SMARCA4 FGFR3 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu SMARCA4 RET 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu SMARCA4 KIT 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu SMARCA4 FGFR3 2
pembrolizumab, paclitaxel, docetaxel, irinotecan SMARCA4 TOP1MT 2
pembrolizumab, paclitaxel, docetaxel, irinotecan SMARCA4 TOP1 2
pembrolizumab, sonidegib SMARCA4 SMO 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMARCA4 RET 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMARCA4 KIT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMARCA4 VEGFA 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMARCA4 FGFR3 2
pemetrexed, bevacizumab SMARCA4 VEGFA 2
pharmacological study, romidepsin SMARCA4 HDAC2 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery SMARCA4 RET 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery SMARCA4 FGFR3 2
regorafenib, laboratory biomarker analysis SMARCA4 RET 2
regorafenib, laboratory biomarker analysis SMARCA4 KIT 2
rubitecan SMARCA4 TOP1 2
sorafenib, administered orally, ct/mri SMARCA4 RET 2
sorafenib, administered orally, ct/mri SMARCA4 KIT 2
topotecan SMARCA4 TOP1MT 2
tucidinostat (chidamide), pd-1 inhibitor (toripalimab), bevacizumab SMARCA4 VEGFA 2
carfilzomib SMARCA4 PSMB5 7
erdafitinib SMARCA4 FGFR3 7
pemigatinib SMARCA4 FGFR3 7
ribociclib SMARCA4 CDK6 7
romidepsin SMARCA4 HDAC2 7
selpercatinib SMARCA4 RET 7
sorafenib SMARCA4 RET 7
sorafenib SMARCA4 KIT 7
trilaciclib SMARCA4 CDK6 7
vandetanib SMARCA4 RET 7
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy SMARCA4 VEGFA 1
3-dimensional conformal radiation therapy, bevacizumab, intensity-modulated radiation therapy, laboratory biomarker analysis, placebo, quality-of-life assessment, temozolomide SMARCA4 VEGFA 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat SMARCA4 HDAC3 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat SMARCA4 HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy (imrt), temozolomide, chloroquine, tumor treating fields therapy (ttf) SMARCA4 TLR9 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat SMARCA4 HDAC3 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat SMARCA4 HDAC2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide SMARCA4 RRM2 1
5 fluorouracil, leucovorin, irinotecan, oxaliplatin SMARCA4 TOP1MT 1
5 fluorouracil, leucovorin, irinotecan, oxaliplatin SMARCA4 TOP1 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan SMARCA4 TOP1MT 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan SMARCA4 TOP1 1
abemaciclib, abemaciclib SMARCA4 CDK6 1
abemaciclib, bevacizumab SMARCA4 VEGFA 1
abemaciclib, bevacizumab SMARCA4 CDK6 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf SMARCA4 TOP1MT 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf SMARCA4 TOP1 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf SMARCA4 CDK6 1
abemaciclib, ly3023414, gemcitabine, capecitabine SMARCA4 CDK6 1
abemaciclib, ly3214996 SMARCA4 CDK6 1
abemaciclib, surgery SMARCA4 CDK6 1
acetazolamide, temozolomide SMARCA4 CA14 1
acetazolamide, temozolomide SMARCA4 CA3 1
actidose aqua, artesunate, amodiaquine SMARCA4 HNMT 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy SMARCA4 HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid SMARCA4 HDAC2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMARCA4 KIT 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMARCA4 CDK6 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMARCA4 BTK 1
afatinib, irinotecan SMARCA4 TOP1MT 1
afatinib, irinotecan SMARCA4 TOP1 1
aldoxorubicin, topotecan SMARCA4 TOP1MT 1
aldoxorubicin, topotecan SMARCA4 TOP1 1
alvocidib, docetaxel SMARCA4 CDK9 1
alvocidib, docetaxel SMARCA4 CDK6 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis SMARCA4 CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis SMARCA4 CDK6 1
amgen 386, bevacizumab SMARCA4 VEGFA 1
aminolevulinic acid SMARCA4 ALAD 1
aminolevulinic acid, surgical resection SMARCA4 ALAD 1
amrubicin, topotecan SMARCA4 TOP1MT 1
amrubicin, topotecan SMARCA4 TOP1 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel SMARCA4 TOP1MT 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel SMARCA4 TOP1 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel SMARCA4 VEGFA 1
anetumab ravtansine, bevacizumab, paclitaxel SMARCA4 VEGFA 1
ang1005, bevacizumab SMARCA4 VEGFA 1
anti-endoglin chimeric monoclonal antibody trc105, bevacizumab, laboratory biomarker analysis, pharmacological study, quality-of-life assessment SMARCA4 VEGFA 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SMARCA4 ALK 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SMARCA4 SMO 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SMARCA4 CDK6 1
asc40 tablets, placebo tablets, bevacizumab SMARCA4 VEGFA 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine SMARCA4 EGLN3 1
at-101, topotecan SMARCA4 TOP1MT 1
at-101, topotecan SMARCA4 TOP1 1
atezolizumab injection, bevacizumab, transarterial chemoembolization SMARCA4 VEGFA 1
atezolizumab, bevacizumab SMARCA4 VEGFA 1
atezolizumab, bevacizumab, laboratory biomarker analysis, pharmacological study SMARCA4 VEGFA 1
atezolizumab, cabozantinib SMARCA4 RET 1
atezolizumab, tivozanib SMARCA4 KIT 1
atorvastatin, temozolomide, radiotherapy SMARCA4 NR1I3 1
atorvastatin, temozolomide, radiotherapy SMARCA4 HDAC2 1
avapritinib, midazolam SMARCA4 KIT 1
avastin, bortezomib SMARCA4 PSMB5 1
avastin, temozolomide, irinotecan SMARCA4 TOP1MT 1
avastin, temozolomide, irinotecan SMARCA4 TOP1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.